Ashley Tate

Founder - Fraqtal Platform

Ashley is an experienced neuroscience researcher and entrepreneur spending the last 5 years working on developing therapies for rare diseases. Most recently she has been leading and managing multiple teams in the development of cell-based therapies for Huntington’s disease. Her work at the University of Rochester Medical Center contributed to pre-Investigational New Drug studies at Oscine Therapeutics which was then acquired by Sana biotechnology. She continues her work with Sana focusing specifically on glial cell therapy. Ashley has a passion for science, social equality, and sustainability. She studied business administration at the University of Rochester focusing on finance and entrepreneurship. She has also developed systems to improve sustainability in growing cities focusing specifically on recycling processes and the gamification of daily “green actions”. Ashley holds an MBA from the Simon school of Business and a Bachelors from Cornell University.